Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Heart Rate Extraction in a Headphone Using Infrared Thermometry.

de Graaf G, Kuratomi Cruz D, Haartsen JC, Hooijschuur F, French PJ.

IEEE Trans Biomed Circuits Syst. 2019 Oct;13(5):1052-1062. doi: 10.1109/TBCAS.2019.2930312. Epub 2019 Jul 23.

PMID:
31352351
2.

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery.

De Meijer L, Merlo D, Skibina O, Grobbee EJ, Gale J, Haartsen J, Maruff P, Darby D, Butzkueven H, Van der Walt A.

Mult Scler J Exp Transl Clin. 2018 Dec 10;4(4):2055217318815513. doi: 10.1177/2055217318815513. eCollection 2018 Oct-Dec.

3.

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Menoyo JLS, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 May;22:166. doi: 10.1016/j.msard.2018.02.025. Epub 2018 Feb 24. No abstract available.

PMID:
29807821
4.

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.

Fragoso YD, Spelman T, Boz C, Alroughani R, Lugaresi A, Vucic S, Butzkueven H, Terzi M, Havrdova E, Horakova D, Granella F, Olascoaga J, Sánchez-Menoyo JL, Pucci E, Barnett M, Brooks JBB, Haartsen J; Lymphopenia and Efficacy of Fingolimod MSBase sub-study Investigators.

Mult Scler Relat Disord. 2018 Jan;19:105-108. doi: 10.1016/j.msard.2017.11.018. Epub 2017 Nov 22.

PMID:
29182993
5.

Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.

de Rooij BH, Ezendam NPM, Nicolaije KAH, Caroline Vos M, Pijnenborg JMA, Boll D, Boss EA, Hermans RHM, Engelhart KCM, Haartsen JE, Pijlman BM, van Loon-Baelemans IEAM, Mertens HJMM, Nolting WE, van Beek JJ, Roukema JA, Kruitwagen RFPM, van de Poll-Franse LV.

Gynecol Oncol. 2017 May;145(2):319-328. doi: 10.1016/j.ygyno.2017.02.041. Epub 2017 Mar 7.

PMID:
28283195
6.

Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial.

Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, Boll D, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, van Loon-Baelemans IE, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Zijlstra WP, Kruitwagen RF, van de Poll-Franse LV.

J Clin Oncol. 2015 Nov 1;33(31):3550-9. doi: 10.1200/JCO.2014.60.3399. Epub 2015 Aug 24.

PMID:
26304900
7.

Association of plasma levels of Protein S with disease severity in multiple sclerosis.

Ma GZ, Giuffrida LL, Gresle MM, Haartsen J, Laverick L, Butzkueven H, Field J, Binder MD, Kilpatrick TJ.

Mult Scler J Exp Transl Clin. 2015 Jul 24;1:2055217315596532. doi: 10.1177/2055217315596532. eCollection 2015 Jan-Dec.

8.

PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.

Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM.

BMC Cancer. 2015 Jun 30;15:487. doi: 10.1186/s12885-015-1487-3.

9.

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.

Gresle MM, Liu Y, Dagley LF, Haartsen J, Pearson F, Purcell AW, Laverick L, Petzold A, Lucas RM, Van der Walt A, Prime H, Morris DR, Taylor BV; Ausimmune Consortium, Shaw G, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1209-13. doi: 10.1136/jnnp-2013-306789. Epub 2014 Mar 17.

PMID:
24639436
10.

Fingolimod after natalizumab and the risk of short-term relapse.

Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, Barnett M, Grand'Maison F, Trojano M, Slee M, Giuliani G, Shaw C, Boz C, Spitaleri DL, Verheul F, Haartsen J, Liew D, Butzkueven H; MSBase Study Group.

Neurology. 2014 Apr 8;82(14):1204-11. doi: 10.1212/WNL.0000000000000283. Epub 2014 Mar 7.

11.

The impact of a cancer Survivorship Care Plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial.

van de Poll-Franse LV, Nicolaije KA, Vos MC, Pijnenborg JM, Boll D, Husson O, Ezendam NP, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, Feijen HW, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Kruitwagen RF.

Trials. 2011 Dec 5;12:256. doi: 10.1186/1745-6215-12-256.

12.

Re: early relapses after the first dose of natalizumab in active multiple sclerosis.

Haartsen J, Marriott M, Butzkueven H.

Mult Scler. 2009 Apr;15(4):520. doi: 10.1177/1352458508100036. No abstract available.

PMID:
19324983
13.

Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study.

van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):125-32. Epub 2007 Jun 4.

PMID:
17544600
14.

Resumption of pituitary and ovarian activity post-partum: endocrine and ultrasonic observations in bromocriptine-treated women.

Haartsen JE, Heineman MJ, Elings M, Evers JL, Lancranjan I.

Hum Reprod. 1992 Jul;7(6):746-50.

PMID:
1500468

Supplemental Content

Loading ...
Support Center